1-[2-[(4S)-4-(tert-butyldimethylsilyloxy)-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(methoxycarbonyl)-6,7-dimethoxynaphthalene | 934192-25-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[2-[(4S)-4-(tert-butyldimethylsilyloxy)-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(methoxycarbonyl)-6,7-dimethoxynaphthalene
• 英文别名: 1-[2-[(4S)-4-(tert-butyldimethylsilyloxy)-1,2,3,4-tetrahydroquinoline-1-yl]-4-pyridyl]-2,3-bis(methoxycarbonyl)-6,7-dimethoxynaphthalene；1-[2-[(4S)-4-(tert-butyldimethyl-silyloxy)-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(methoxycarbonyl)-6,7-dimethoxynaphthalene；dimethyl 1-[2-[(4S)-4-[tert-butyl(dimethyl)silyl]oxy-3,4-dihydro-2H-quinolin-1-yl]pyridin-4-yl]-6,7-dimethoxynaphthalene-2,3-dicarboxylate
• CAS: 934192-25-3
• 化学式: C₃₆H₄₂N₂O₇Si
• 分子量: 642.824
• InChiKey: OSAICBOXRLIVSF-NDEPHWFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  46
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  96.4
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1-[2-[(4S)-4-(tert-butyldimethylsilyloxy)-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(methoxycarbonyl)-6,7-dimethoxynaphthalene 在 sodium tetrahydroborate 、 四丁基氟化铵 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 10.0h， 生成 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene
  参考文献：
  名称：

  Naphthalene derivatives for the treatment of dermatitis and psoriasis

  摘要：

  公开号：

  EP1941881B1
• 作为产物：
  描述：

  2,3-二氢-1H-喹啉-4-酮 在 palladium diacetate 、 palladium on activated charcoal 、 tri tert-butylphosphoniumtetrafluoroborate 咪唑 、 硼烷四氢呋喃络合物 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 33.33h， 生成 1-[2-[(4S)-4-(tert-butyldimethylsilyloxy)-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(methoxycarbonyl)-6,7-dimethoxynaphthalene
  参考文献：
  名称：

  Naphthalene derivatives for the treatment of dermatitis and psoriasis

  摘要：

  公开号：

  EP1941881B1

文献信息

• Dermatitis treating agent
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US07868019B2

  公开（公告）日：2011-01-11

  The present invention is to provide a topical dermatitis treating agent which comprises a pyridine compound represented by the following formula [I]: wherein R1 and R2 each represent a lower alkoxy group, ═X— represents a group represented by the formula: or a group represented by the formula: ═N—, Ring A represents a saturated or unsaturated bicyclic nitrogen-containing heterocyclic group having 1 to 4 substituents selected from hydroxyl group, oxo group, a lower alkoxy group, a di-lower alkylaminophenyl group, a pyperidino-lower alkoxy group, a morpholino-lower alkoxy group, a cyclo-lower alkylamino-lower alkylamino group, pyridyl group and morpholino group, and represents a single bond or a double bond, or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明提供了一种局部治疗皮炎的药剂，其包含以下式[I]所表示的吡啶化合物，其中R1和R2各代表较低的烷氧基，═X—代表由以下式表示的基团：或由以下式表示的基团：═N—，环A代表具有1到4个取代基的饱和或不饱和的含氮杂环，所述取代基从羟基、氧代基、较低的烷氧基、二较低的烷基氨基苯基、吡哆啉较低的烷氧基、吗啉较低的烷氧基、环较低的烷基氨基较低的烷基氨基基、吡啶基和吗啉基中选择，并且表示单键或双键，或其药学上可接受的盐作为活性成分。
• DERMATITIS TREATING AGENT (AS AMENDED)
  申请人：Naotsuka Atsuko

  公开号：US20100130494A1

  公开（公告）日：2010-05-27

  The present invention is to provide a topical dermatitis treating agent which comprises a pyridine compound represented by the following formula [I]: wherein R 1 and R 2 each represent a lower alkoxy group, ═X— represents a group represented by the formula: or a group represented by the formula: ═N—, Ring A represents a saturated or unsaturated bicyclic nitrogen-containing heterocyclic group having 1 to 4 substituents selected from hydroxyl group, oxo group, a lower alkoxy group, a di-lower alkylaminophenyl group, a pyperidino-lower alkoxy group, a morpholino-lower alkoxy group, a cyclo-lower alkylamino-lower alkylamino group, pyridyl group and morpholino group, and represents a single bond or a double bond, or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明提供了一种局部治疗皮炎的药剂，其包含下式[I]所表示的吡啶化合物：其中R1和R2各代表低烷氧基，═X—代表由以下式表示的基团：或由以下式表示的基团：═N—，环A代表具有1至4个取代基（所选的是羟基、氧代基、低烷氧基、二低烷基氨基苯基、吡啶基低烷氧基、吗啉基低烷氧基、环状低烷基氨基-低烷基氨基基、吡啶基和吗啉基）的饱和或不饱和双环氮杂环基，且表示单键或双键，或其药学上可接受的盐作为活性成分。
• OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME
  申请人：OKAMOTO Masaki

  公开号：US20110196157A1

  公开（公告）日：2011-08-11

  The present invention relates to a method for preparing an optically active cyclic alcohol compound represented by general formula [I]: [wherein R represents a hydrogen atom or a protecting group for amino group, and * represents an asymmetric carbon atom.] which comprises a step of subjecting a cyclic ketone compound represented by general formula [II]: [wherein R has the same meaning as defined above.] to asymmetric reduction (A) in the presence of an optically active oxazaborolidine compound and a boron hydride compound, or (B) in the presence of an asymmetric transition metal complex obtained from a transition metal compound and an asymmetric ligand and a hydrogen donor, and relates to said compound.

  本发明涉及一种制备光学活性环状醇化合物的方法，该化合物由通式[I]表示：[其中R表示氢原子或氨基保护基，*表示不对称碳原子]，包括以下步骤：将通式[II]表示的环状酮化合物[其中R具有上述定义的相同含义]在光学活性氧杂硼酮化合物和硼氢化合物的存在下进行不对称还原（A），或在过渡金属化合物和不对称配体以及氢供体得到的不对称过渡金属配合物的存在下进行不对称还原（B），并涉及该化合物。
• Optically Active Cyclic Alcohol Compound And Method For Preparing The Same
  申请人：Okamoto Masaki

  公开号：US20130237708A1

  公开（公告）日：2013-09-12

  The present invention relates to a method for preparing an optically active cyclic alcohol compound represented by general formula [I]: [wherein R represents a hydrogen atom or a protecting group for amino group, and * represents an asymmetric carbon atom.] which comprises a step of subjecting a cyclic ketone compound represented by general formula [II]: [wherein R has the same meaning as defined above.] to asymmetric reduction (A) in the presence of an optically active oxazaborolidine compound and a boron hydride compound, or (B) in the presence of an asymmetric transition metal complex obtained from a transition metal compound and an asymmetric ligand and a hydrogen donor, and relates to said compound.

  本发明涉及一种制备光学活性环状醇化合物的方法，该化合物由通式[I]表示：[其中R代表氢原子或氨基保护基，*代表不对称碳原子]，包括以下步骤：将通式[II]表示的环状酮化合物[其中R的含义与上述定义相同]在光学活性氧杂硼烷化合物和硼氢化合物的存在下进行不对称还原（A），或者在从过渡金属化合物和不对称配体获得的不对称过渡金属络合物和氢供体的存在下进行不对称还原（B），并涉及该化合物。
• Optically active cyclic alcohol compound and method for preparing the same
  申请人：Okamoto Masaki

  公开号：US08754221B2

  公开（公告）日：2014-06-17

  The present invention relates to a method for preparing an optically active cyclic alcohol compound represented by general formula [I]: [wherein R represents a hydrogen atom or a protecting group for amino group, and * represents an asymmetric carbon atom.] which comprises a step of subjecting a cyclic ketone compound represented by general formula [II]: [wherein R has the same meaning as defined above.] to asymmetric reduction (A) in the presence of an optically active oxazaborolidine compound and a boron hydride compound, or (B) in the presence of an asymmetric transition metal complex obtained from a transition metal compound and an asymmetric ligand and a hydrogen donor, and relates to said compound.

  本发明涉及一种制备光学活性环状醇化合物的方法，该化合物由通式[I]表示：[其中R表示氢原子或氨基的保护基，*表示不对称碳原子]，该方法包括将通式[II]表示的环状酮化合物进行不对称还原的步骤：[其中R的含义与上述定义相同]，在存在光学活性氧杂硼烷化合物和硼氢化物的条件下进行(A)，或在存在由过渡金属化合物和不对称配体得到的不对称过渡金属配合物和氢供体的条件下进行(B)，并涉及该化合物。